It was FDA-approved in 2019 as Vyleesi. It works in the brain, not the blood vessels. Here's what that means and why it matters.
Research context only. PT-141 is FDA-approved as Vyleesi for a specific indication. All other use is off-label. Not medical advice.
PT-141 (bremelanotide) is a synthetic peptide that works on the brain to increase sexual desire. It's derived from Melanotan II — a tanning peptide — after researchers noticed that Melanotan II had a pronounced side effect: spontaneous arousal. PT-141 was developed specifically to isolate and harness that effect without the tanning component.
In 2019, PT-141 was FDA-approved under the brand name Vyleesi for treating hypoactive sexual desire disorder (HSDD) in premenopausal women — making it one of only two FDA-approved medications for female sexual dysfunction, and the only one that works centrally (in the brain) rather than peripherally.
The key distinction: Viagra and Cialis work by increasing blood flow to the genitals — a vascular, peripheral mechanism. PT-141 works in the brain, activating pathways that create desire itself. This is why it works for people for whom vascular drugs don't — and why it has a different side effect profile.
PT-141 is a melanocortin receptor agonist — it binds MC3R and MC4R receptors, which are found primarily in the hypothalamus and limbic system (the brain's emotional and reward centers).
MC4R activation in the hypothalamus triggers dopamine release in the mesolimbic system — the same pathway involved in reward, motivation, and desire. This is the mechanism behind the increase in sexual motivation and arousal.
Unlike PDE5 inhibitors, PT-141 doesn't require vascular function to work. It generates desire centrally — which means it can work even when vascular-based approaches fail, and it works in both men and women.
Why this matters clinically: A significant portion of sexual dysfunction has a psychological or neurological component that vascular drugs don't address. PT-141's central mechanism fills that gap. The FDA's approval for HSDD specifically recognized that desire disorders require a central, not peripheral, solution.
The Phase 3 trials that led to FDA approval enrolled premenopausal women with HSDD. The primary endpoints were number of satisfying sexual events per month and reduction in distress associated with low desire. Results showed statistically significant improvements on both measures versus placebo.
Off-label research in men has shown effects on erectile function and sexual motivation, though this indication wasn't pursued through formal Phase 3 trials. The central mechanism makes it theoretically applicable to desire disorders in both sexes.
The nausea issue: Nausea is the most common side effect of PT-141 and the primary reason for discontinuation in clinical trials (~40% of participants reported it). Starting at 1mg rather than 2mg and having a light meal beforehand significantly reduces nausea incidence. This is the most important practical consideration for new researchers.
The blood pressure finding is why Vyleesi's label advises against use in people with cardiovascular disease and recommends blood pressure monitoring. This is the most clinically significant safety signal from the trials.
Completely different mechanism. Viagra works on penile vasculature; PT-141 works in the brain's desire pathways. They can be used together — they don't compete mechanistically — but they address different aspects of sexual function.
PT-141 was approved specifically for women with HSDD because that's the population studied in Phase 3. The melanocortin mechanism works in both sexes. Off-label research in men has shown effects on desire and erectile function.
Nausea increases significantly with dose. Most researchers find 1mg is sufficient for initial use, with 1.5mg being a common sweet spot. Going straight to 2mg dramatically increases nausea probability for first-time users.
COA-verified vendor pricing with promo codes, reconstitution guide, and dosing protocol.
View Pricing → Dosage Calculator